Barr and Aventis file suit over Allegra-D patents
US generics firm Barr Laboratories and Aventis Pharmaceuticals havecrossed legal swords in the first round of a patent dispute over the latter's Allegra-D (fexofenadine hydrochloride 60mg and pseudophedrine hydrochloride 120mg) in the USA. The lawsuit was stimulated by Barr's decision to file for approval of a generic version of Allegra-D, which is thought to have annual sales in excess of $350 million, and the US Food and Drug Administration's acceptance of that filing.
Barr and Aventis are already in dispute over capsule and tablet forms of Allegra-D (Marketletter July 9, 2001). Sales of the entire Allegra franchise were 1.25 billion euros ($1.08 billion) in the first nine months of 2001, with 1.04 billion euros of that total coming from the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze